Sanuwave Health licenses intravascular shockwave patents for $2.5M; extends debt forbearance to April 30, 2024

SANUWAVE Health, Inc.

Licensed intravascular shockwave patent portfolio to Vascular Wave LLC for $2.5M upfront; option to acquire for additional single-digit millions.
Noteholders consented to the license and waived related defaults; forbearance on existing defaults continued until April 30, 2024.
Patents released from NPA collateral; default rate interest continues to accrue during forbearance.
Company remains in default but avoids immediate enforcement; must still comply with all other obligations under NPA.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

SANUWAVE Health, Inc. amended Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase Agreement with NH Expansion Credit Fund Holdings LP (effective 2024-03-06).

Action: amendment
Counterparty: NH Expansion Credit Fund Holdings LP
Effective: 2024-03-06

Exact text from the filing

On March 6, 2024, Sanuwave Health, Inc. (the “Company”) entered into a Consent, Limited Waiver and Fifth Amendment to Note and Warrant Purchase Agreement (the “Fifth Amendment”) with NH Expansion Credit Fund Holdings LP (the “Agent”) and the noteholders party thereto (the “Holders”).

View on SEC.gov

739 material agreements filed in the last 30 days. Browse all material agreements →

SANUWAVE Health, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-24-011798

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.